A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease

ClinicalTrials.gov ID: NCT05744401

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT05744401. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 5:50 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Long-term Extension Study to Evaluate the Safety, Tolerability, and Efficacy of AL002 in Participants With Alzheimer's Disease

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A long-term extension study to evaluate the safety, tolerability, and efficacy of AL002 in participants with Early Alzheimer's Disease.

Study identification

NCT ID: NCT05744401
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 2
Lead sponsor: Alector Inc.; Industry
Enrollment: 197 participants

Conditions and interventions

Conditions

Alzheimer's Disease

Interventions

AL002 Drug

Drug

Eligibility (public fields only)

Age range: 50 Years to 85 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 4, 2023 (Actual)
Primary completion: Jan 31, 2025 (Actual)
Completion: Feb 5, 2025 (Actual)
Last update posted: Feb 25, 2026

2023 – 2025

United States locations

U.S. sites: 15
U.S. states: 8
U.S. cities: 15

Facility	City	State	ZIP	Site status
Banner Alzheimer's Institute	Phoenix	Arizona	85006	—
Georgetown University Medical Center	Washington D.C.	District of Columbia	20007	—
SFM Clinical Research, LLC	Boca Raton	Florida	33487	—
Charter Research	Lady Lake	Florida	32159	—
K2 Medical Research - Maitland	Maitland	Florida	32751	—
Progressive Medical Research - ClinEdge - PPDS	Port Orange	Florida	32127	—
Axiom Brain Health LLC	Tampa	Florida	33609	—
"Alzheimers Research and Treatment Center-Wellington "	Wellington	Florida	33449	—
Conquest Research LLC - Winter Park - ClinEdge - PPDS	Winter Park	Florida	32819	—
Hattiesburg Clinic	Hattiesburg	Mississippi	39401	—
Advanced Clinical Institute	Neptune City	New Jersey	07753	—
Feinstein Institute For Medical Research	Manhasset	New York	11030	—
SUNY Upstate Medical Center	Syracuse	New York	13210	—
University of Cincinnati Medical Center	Cincinnati	Ohio	45219	—
Summit Research Network	Portland	Oregon	97210	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 39 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05744401, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 25, 2026 · Synced Nov 13, 2026